Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 2011. The report details a specific share repurchase transaction executed on July 11, 2011, pursuant to shareholder authority granted at the Annual General Meeting on May 5, 2011.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on capital structure changes related to share buybacks.
- Shares Purchased: 1,500,000 Ordinary shares of 25 pence each.
- Price Range: Highest price paid was 1,375.0 pence per share; lowest price paid was 1,360.0 pence per share.
- Treasury Holdings (Settled): 475,054,284 shares (8.48% of total issued share capital).
- Treasury Holdings (Including Unsettled): 478,934,284 shares (9.34% of total voting rights).
- Shares in Issue (Excluding Treasury): 5,128,042,677 shares.
Material Changes
The primary material change is the reduction of outstanding shares through the purchase of 1,500,000 shares. Consequently, the Company's treasury holdings increased to represent 8.48% of total issued share capital, or 9.34% of total voting rights when including unsettled purchases.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on operational outlook, or discussion of risks and contingencies. The shares purchased are intended to be held in Treasury.
Investor Verification Checklist
- Verify the total number of shares held in Treasury (475,054,284 settled) against the total issued share capital.
- Confirm the impact of the 9.34% treasury holding on total voting rights calculations.
- Check the remaining authorization for share repurchases under the mandate granted on May 5, 2011.
- Review the Financial Services Authority's Disclosure and Transparency Rules regarding the 5,128,042,677 shares in issue for notification thresholds.